With over 110,000 confirmed cases and nearly 4,000 deaths worldwide, the COVID-19 pandemic is understandably alarming. As public health experts monitor developments closely, several positive indicators provide grounds for measured optimism and underscore why panic is unnecessary.
Anxiety is widespread in France and globally, yet a critical fact stands out: of the 110,000 COVID-19 cases, 60,000 individuals have already recovered. The mortality rate remains relatively low at 3,800 deaths—roughly 13 times fewer than recoveries.
Over 80% of cases are mild, involving no symptoms or only minor ones. Around 15% progress to severe pneumonia, while the remaining 5% become critical, potentially leading to fatalities. Notably, the virus spares children almost entirely, though they may act as asymptomatic carriers.
Scientific progress on COVID-19 advances daily. The virus has been identified, its genome fully sequenced, and reliable detection methods established—though asymptomatic cases and mutations pose ongoing challenges. Already, 250 peer-reviewed articles cover diagnostics, vaccines, therapies, and genetics.
Vaccine development is underway across eight projects, including efforts by U.S. firms Inovio Pharmaceuticals and Moderna, plus France's Sanofi. Meanwhile, 80 clinical trials evaluate antivirals like remdesivir and chloroquine, originally a malaria treatment.
While new hotspots emerge in South Korea, Italy, and Iran, China's original epicenter shows clear improvement. With 81,000 cases and 3,119 deaths, daily new infections and fatalities are steadily declining.
This stems from stringent quarantine measures in Wuhan, Hubei Province, and other cities, paired with nationwide transport restrictions to curb spread.
The slowdown has also slashed pollution, as evidenced by recent NASA satellite imagery.
Source
Related Articles:
